Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02043301 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetics And Relative Bioavailability Of Bococizumab (PF-04950615; RN316) When Administered To The Abdomen, Thigh Or Upper Arm
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 75
- Enrollment target
NCT02043301 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 75 participants.
The verdict
NCT02043301, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 75 participants
- Enrollment target
Study Summary
This study aims to characterize the single dose pharmacokinetics of PF-04950616 following subcutaneous injection to the abdomen, upper arm or the thigh.
Interventions
- BIOLOGICAL Bococizumab (PF-04950615; RN316)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2014-04 |
| Est. Completion | 2014-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02043301
The ClinicalTrials.gov registry entry for NCT02043301 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Bococizumab (PF-04950615; RN316) is the first listed.
NCT02043301 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02043301 about?
NCT02043301 is a clinical study titled "Pharmacokinetics And Relative Bioavailability Of Bococizumab (PF-04950615; RN316) When Administered To The Abdomen, Thigh Or Upper Arm". This study aims to characterize the single dose pharmacokinetics of PF-04950616 following subcutaneous injection to the abdomen, upper arm or the thigh.
What is the current status of trial NCT02043301?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 75 participants. The study started on 2014-04. Estimated completion is 2014-11.
What interventions are being tested in trial NCT02043301?
The interventions under investigation include: Bococizumab (PF-04950615; RN316) (BIOLOGICAL).
Who is sponsoring clinical trial NCT02043301?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.